Brinzolamide ophthalmic suspension — Competitive Intelligence Brief

Brinzolamide ophthalmic suspension (Brinzolamide ophthalmic suspension) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Carbonic anhydrase inhibitor. Area: Ophthalmology.

phase 3 Carbonic anhydrase inhibitor Carbonic anhydrase II Ophthalmology Small molecule

Target snapshot

Brinzolamide ophthalmic suspension (Brinzolamide ophthalmic suspension) — Sun Pharmaceutical Industries Limited. Brinzolamide is a carbonic anhydrase inhibitor that reduces aqueous humor production in the eye, thereby lowering intraocular pressure.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Brinzolamide ophthalmic suspension TARGET	Brinzolamide ophthalmic suspension	Sun Pharmaceutical Industries Limited	phase 3	Carbonic anhydrase inhibitor	Carbonic anhydrase II
Azopt	BRINZOLAMIDE	Novartis	marketed	Carbonic Anhydrase Inhibitor [EPC]	carbonic anhydrase II	1998-01-01
ACETAZOLAMIDE oral capsule	ACETAZOLAMIDE oral capsule	University of Zurich	marketed	Carbonic anhydrase inhibitor	Carbonic anhydrase II
treatment with dorzolamide/timolol	treatment with dorzolamide/timolol	Aristotle University Of Thessaloniki	marketed	Carbonic anhydrase inhibitor / Beta-blocker combination	Carbonic anhydrase II; Beta-adrenergic receptors (β1 and β2)
Brinzolamide/Brimonidine FC	Brinzolamide/Brimonidine FC	University Hospital of Patras	marketed	Carbonic anhydrase inhibitor / Alpha-2 adrenergic agonist combination	Carbonic anhydrase II; Alpha-2 adrenergic receptor
Dorzolamide 2% drops	Dorzolamide 2% drops	University Health Network, Toronto	marketed	Carbonic anhydrase inhibitor	Carbonic anhydrase II
timolol maleate and dorzolamide hydrochloride	timolol maleate and dorzolamide hydrochloride	University of Florida	marketed	Beta-adrenergic antagonist and carbonic anhydrase inhibitor combination	Beta-2 adrenergic receptor (timolol); carbonic anhydrase II (dorzolamide)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Carbonic anhydrase inhibitor class)

1. Bausch & Lomb Incorporated · 2 drugs in this class
2. Actavis Inc. · 2 drugs in this class
3. Beijing Tiantan Hospital · 1 drug in this class
4. Merck Sharp & Dohme LLC · 1 drug in this class
5. National University Hospital, Singapore · 1 drug in this class
6. Padagis LLC · 1 drug in this class
7. Rabin Medical Center · 1 drug in this class
8. Shahid Beheshti University of Medical Sciences · 1 drug in this class
9. Sun Pharmaceutical Industries Limited · 1 drug in this class
10. University Health Network, Toronto · 1 drug in this class